A dose escalation study designed to demonstrate the safety, tolerability and efficacy of the fully human anti-TNF antibody, D2E7, given in combination with methotrexate (MTX) in patients with active RA.

被引：0
|
作者：
Weisman, M
Keystone, E
Paulus, H
Weinblatt, M
Furst, D
Moreland, L
Velagapudi, R
Fischkoff, S
Chartash, E
机构：
来源：
ARTHRITIS AND RHEUMATISM | 2000年 / 43卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1948
引用
收藏
页码：S391 / S391
页数：1
相关论文
共 40 条
  • [1] Generation of fully human anti-TNF antibody D2E7
    Salfield, J
    Kaymakçalan, J
    Tracey, D
    Roberts, A
    Kamen, R
    ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S57 - S57
  • [2] The ARMADA trial: A double-blind placebo controlled trial of the fully human anti-TNF monoclonal antibody, adalimumab (D2E7), in patients with active RA on methotrexate (MTX).
    Keystone, E
    Weinblatt, M
    Furst, D
    Weisman, M
    Moreland, L
    Birbara, C
    Fischkoff, S
    Chartash, E
    ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S213 - S213
  • [3] The effect of D2E7, a new human anti-TNFα monoclonal antibody, on the oxidative burst of PMN in patients with RA.
    den Broeder, AA
    Wanten, GJA
    van Riel, PLCM
    Kroot, EJ
    Naber, THJ
    Barrera, P
    ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S57 - S57
  • [4] Efficacy of the fully human anti-TNF antibody D2E7 in rheumatoid arthritis.
    van de Putte, BA
    Rau, R
    Breedveld, FC
    Kalden, JR
    Malaise, MG
    Schattenkirchner, M
    Emery, P
    Burmester, GR
    Zeidler, H
    Moutsopoulos, HH
    Compagnone, D
    Kempeni, J
    Kupper, H
    ARTHRITIS AND RHEUMATISM, 1999, 42 (09): : S400 - S400
  • [5] Long-term use of the fully human anti-TNF antibody D2E7 in combination with methotrexate in active rheumatoid arthritis.
    Schattenkirchner, M
    Wastlhuber, J
    Rau, R
    Herborn, G
    Kroot, EJ
    van Riel, PLCM
    van de Putte, LBA
    Ailaart, CF
    Breedveld, FC
    Fenner, H
    Theophil, E
    Kempeni, J
    Kupper, H
    ARTHRITIS AND RHEUMATISM, 2000, 43 (09): : S228 - S228
  • [6] One year efficacy results of the fully human anti-TNF antibody D2E7 in rheumatoid arthritis.
    van de Putte, LBA
    Rau, R
    Breedveld, FC
    Kalden, JR
    Malaise, MG
    Schattenkirchner, M
    Emery, P
    Burmester, GR
    Zeidler, H
    Dressler, R
    Compagnone, D
    Kempeni, J
    Kupper, H
    ARTHRITIS AND RHEUMATISM, 2000, 43 (09): : S269 - S269
  • [7] A single dose placebo controlled phase 1 study of the fully human anti-TNF antibody D2E7 in patients with rheumatoid arthritis.
    van de Putte, LBA
    van Riel, PLCM
    den Broeder, A
    Sander, O
    Rau, R
    Binder, C
    Krüger, K
    Schattenkircher, M
    Fenner, H
    Salfeld, J
    Bankmann, Y
    Kupper, H
    Kempeni, J
    ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S57 - S57
  • [8] Improvement in health utility among rheumatoid arthritis (RA) patients treated with adalimumab (D2E7),a fully human anti-TNF monoclonal antibody
    van de Putte, L
    Boggs, R
    Sengupta, N
    Dietz, B
    Bergemann, R
    Rosery, H
    Kupper, H
    VALUE IN HEALTH, 2002, 5 (06) : 461 - 461
  • [9] Preliminary results of early clinical trials with the fully human anti-TNFα monoclonal antibody D2E7
    Kempeni, J
    ANNALS OF THE RHEUMATIC DISEASES, 1999, 58 : 70 - 72
  • [10] Safety and efficacy of adalimumab (D2E7), a fully human Anti-TNF-α monoclonal antibody, given in combination with standard antirheumatic therapy:: Safety trial of adalimumab in rheumatoid arthritis (STAR).
    Furst, DE
    Schiff, M
    Fleischmann, R
    Birbara, C
    Strand, V
    Compagnone, D
    Chartash, E
    ARTHRITIS AND RHEUMATISM, 2002, 46 (09): : S572 - S572
1234